NCT04251715View on ClinicalTrials.gov

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

November 30, 2025

Conditions
Liver and Intrahepatic Bile Duct CarcinomaStage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Dexamethasone

Given intraarterially via HAI pump

DRUG

Floxuridine

Given intraarterially via HAI pump

DEVICE

Implanted Medical Device

Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy

DRUG

Irinotecan

Given IV

DRUG

Leucovorin

Given IV

DRUG

Oxaliplatin

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER